According to GEN website, Regeneron Pharmaceuticals recently had granted Intellia Therapeutics gene editing technology. This cooperation will bring more than 125 million dollars revenue to Intellia Therapeutics, and the advance payment is $ 75 million.

According to the six-year agreement, Regeneron has exclusive product right that develops up to 10 targets and based in CRISPR , wherein Regeneron can choose five nonliver target. It is noteworthy that, this cooperation is not including Intellia’s ongoing research program  non-target liver and another involved in Intellia’s other cooperation.

The first cooperation project between the two sides is aimed at treating Transthyretin Amyloidosis disease. In addition to focus on new therapies, the two sides will also focus on the development of CRISPR / Cas platform.

On the same day, according to Xconomy website, Intellia had submitted its listing documents, and the initial goal of IPO is $ 120 million. Its Cambridge "neighbor" Editas Medicine had raised $ 94 million fund in February’s IPO this year. Intellia wants to “send” the role of genes in the CRISPR to liver cells. Through the patient's blood, cut DNA and help treat liver disease.

Intellia hopes that through lipid nanoparticles technology, CRISPR will be presented to   liver cells, which licensed from Novartis. The company is also committed to overcome the α-1 antitrypsin deficiency, HBV infection, liver disease, and congenital metabolic disorders. It shows in its IPO prospectus that in the next 1 to 2 years, the company hopes to have one or two liver disease items pointed toward clinical trials.